Aesica Pharmaceuticals, an innovative supplier of contract development and manufacturing solutions, has entered into a new multi-year supply agreement with Amdipharm. Under the new contract Aesica will provide manufacturing and packaging services for several of Amdipharm’s leading products for supply to worldwide markets. Initially, the products covered include Erythrocin (erythromycin), Hytrin (terazosin) and Loftyl (buflomedil), and the range is likely to expand in the future.
Manufacturing operations are carried out at Aesica’s finished dosage pharmaceutical production facility located in Queenborough, Kent, UK. The award-winning site is equipped with extensive process technologies including capabilities for the manufacture of solid and liquid dosage forms, anaesthetics and controlled drugs, and facilities for packaging in blister packs, sachets and bottles. Aesica’s support to Amdipharm includes analytical, regulatory and supply chain services.
Amdipharm is an emerging global pharmaceutical enterprise and has its priority to supply essential prescription medicines to meet real clinical needs. Mick Cullen, managing director of Amdipharm Sales and Marketing, said: "We have been very pleased with our growing relationship with Aesica based on their reliability, flexibility and responsiveness."
Adam Sims, commercial director of Aesica, said: "We have worked hard to ensure the smooth transfer of the new Amdipharm products into the Queenborough site. We are proud of our record of handling the complex multi-country supply and the wide range of product volumes."
For more information please visit Aesica at CPhI, Feria de Madrid (IFEMA), between 13 and 15 October, at stand number 4B29 in hall 4, or contact Maria Koustareva, Aesica’s marketing manager.
Twitter